Home › Funds › ORBIMED ADVISORS LLC › NKTR
ORBIMED ADVISORS LLC position in NKTR
NEKTAR THERAPEUTICS · Health Care
ORBIMED ADVISORS LLC reported holding 465,346 shares of NKTR (NEKTAR THERAPEUTICS) in its Q2 2026 13F filing — a position valued at US$32.5M, representing 0.65% of its reported portfolio and ranking #42 among its reported holdings. ORBIMED ADVISORS LLC has disclosed NKTR holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How ORBIMED ADVISORS LLC's NKTR position evolved
ORBIMED ADVISORS LLC first disclosed a stake in NKTR in Q1 2026 at 275,000 shares (US$19.8M). The position peaked in Q2 2026 at 465,346 shares, worth US$32.5M. Across 2 filings, ORBIMED ADVISORS LLC increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 465,346 shares valued at US$32.5M — an increase of 190,346 shares quarter over quarter.. Notable position changes include a 69% increase in Q2 2026 (shares fell 13% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 275.00K | $19.79M | New |
| Q2 2026 | 465.35K | $32.49M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About NKTR and 13F data
NKTR (NEKTAR THERAPEUTICS) is a Health Care company. 70 other funds we track also report a position in NKTR — the largest reported positions include Two Seas Capital LP (US$202.6M), BVF INC/IL (US$166.9M), Vestal Point Capital, LP (US$69.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding NKTR
- Two Seas Capital LP 3.35M sh · $202.58M · Q3 2026
- BVF INC/IL 2.39M sh · $166.92M · Q2 2026
- Vestal Point Capital, LP 1.00M sh · $69.81M · Q2 2026
- Prosight Management, LP 810.00K sh · $56.55M · Q2 2026
- ARMISTICE CAPITAL, LLC 724.00K sh · $50.54M · Q2 2026
- BRAIDWELL LP 473.62K sh · $33.06M · Q2 2026
- Sofinnova Investments, Inc. 471.76K sh · $32.93M · Q2 2026
- DAFNA Capital Management LLC 318.38K sh · $22.23M · Q2 2026
- 22NW, LP 281.12K sh · $19.62M · Q2 2026
- ADAR1 Capital Management, LLC 244.18K sh · $17.05M · Q2 2026
- Creek Drive Management Group LLC 243.00K sh · $16.96M · Q2 2026
- SEVEN GRAND MANAGERS, LLC 240.00K sh · $16.75M · Q2 2026
More on ORBIMED ADVISORS LLC
FAQ
How long has ORBIMED ADVISORS LLC held NKTR?
ORBIMED ADVISORS LLC has disclosed NKTR holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
What is ORBIMED ADVISORS LLC's current position in NKTR?
As of Q2 2026, ORBIMED ADVISORS LLC holds 465.35K shares of NKTR (NEKTAR THERAPEUTICS), valued at $32.49M, representing 0.65% of its reported portfolio and ranking #42.
Has ORBIMED ADVISORS LLC been buying or selling NKTR?
In the latest 13F filing (Q2 2026), ORBIMED ADVISORS LLC increased its position in NKTR. The position peaked in Q2 2026 at 465.35K shares.
Which other funds hold NKTR?
Other major institutional holders of NKTR include Two Seas Capital LP, BVF INC/IL, Vestal Point Capital, LP, among 70 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.